Suffering from Depression? Help us find new treatments!
What is SGLT2-MDD?
This is an in-person research study that aims to understand the effect of empagliflozin, a medication part of the class of sodium-glucose cotransporter-2 (SGLT2) inhibitors, in depression. Since this medication simulates the metabolic effects of the “ketogenic diet,” which some studies suggest improves mood, this study will also help us understand how problems with mood might relate to how the brain uses energy.
You may be eligible if:
. You are between the ages of 18-65 (inclusive)
. You have a diagnosis of major depressive disorder
. You reside in the greater New York City area
If you are interested, please respond with your name and phone number! Our study team will give you a call with more information.
